Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors

Human Pathology

Volumn 39, Issue 8, 2008, Pages 1205-1211

  Li, Lin ^a   Xu, Haodong ^a   Spaulding, Betsy O ^b   Cheng, Liang ^c   Simon, Rochelle ^a   Yao, Jorge L ^a   di Sant'Agnese, P Anthony ^a   Bourne, Patricia A ^a   Huang, Jiaoti ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b AGILENT TECHNOLOGIES   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; IMP3; p16; p53; Urothelial neoplasia

Indexed keywords

PROTEIN P16; PROTEIN P53; RNA BINDING PROTEIN; RNA BINDING PROTEIN IMP3;

ADULT; ARTICLE; BENIGN TUMOR; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; TUMOR DIAGNOSIS; UROGENITAL TRACT TUMOR; UROTHELIUM;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 47649122801     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.12.012     Document Type: Article

References (35)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Mhawech-Fauceglia P., Cheney R.T., and Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106 (2006) 1205-1216
3. Spiess P.E., and Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130 (2006) 844-852
4. Mitra A.P., Datar R.H., and Cote R.J. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 24 (2006) 5552-5564
5. Eble J.N., S G., Epstein J.I., and Sesterhenn I.A. World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs (2004), IARC Press, Lyon
6. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119 (2006) 1513-1518
7. Helpap B., Schmitz-Drager B.J., Hamilton P.W., et al. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 442 (2003) 309-316
8. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
9. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
10. Hernando E., Nahle Z., Juan G., et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430 (2004) 797-802
11. Florl A.R., Franke K.H., Niederacher D., et al. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 80 10 (2000) 1513-1522
12. Chapman E.J., Harnden P., Chambers P., Johnston C., and Knowles M.A. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 11 (2005) 5740-5747
13. Williamson M.P., Elder P.A., Shaw M.E., Devlin J., and Knowles M.A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4 (1995) 1569-1577
14. Reznikoff C.A., Sarkar S., Julicher K.P., et al. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 5 (2000) 191-203
15. Baithun S.I., Naase M., Blanes A., and Diaz-Cano S.J. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 438 (2001) 289-297
16. Mueller-Pillasch F., Lacher U., Wallrapp C., et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14 (1997) 2729-2733
17. Nielsen J., Christiansen J., Lykke-Andersen J., et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19 (1999) 1262-1270
18. Liao B., Hu Y., Herrick D.J., and Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280 (2005) 18517-18524
19. Yantiss R.K., Woda B.A., Fanger G.R., et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29 (2005) 188-195
20. Xu H., Bourne P.A., Spaulding B.O., and Wang H.L. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 38 (2007) 555-563
21. Simon R., Bourne P.A., Yang Q., et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol (2007)
22. Li C., Rock K.L., Woda B.A., et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 20 (2007) 242-247
23. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7 (2006) 556-564
24. Huang J., Yao J.L., Zhang L., et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 166 (2005) 1807-1815
25. Prince S.N., Foulstone E.J., Zaccheo O.J., Williams C., and Hassan A.B. Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor. Mol Cancer Ther 6 (2007) 607-617
26. LeRoith D., and Roberts Jr. C.T. The insulin-like growth factor system and cancer. Cancer Lett 195 (2003) 127-137
27. Foulstone E., Prince S., Zaccheo O., et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205 (2005) 145-153
28. Fichera E., Liang S., Xu Z., et al. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 10 (2000) 61-70
29. Torrisi R., Mezzetti M., Johansson H., et al. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87 (2000) 601-605
30. Cote R.J., and Chatterjee S.J. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 5 (1999) 2-15
31. Esrig D., Spruck III C.H., Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143 (1993) 1389-1397
32. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56 (1994) 347-353
33. Stadler W.M., Sherman J., Bohlander S.K., et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 54 (1994) 2060-2063
34. Stadler W.M., Steinberg G., Yang X., et al. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 7 (2001) 1676-1682
35. Friedrich M.G., Blind C., Milde-Langosch K., et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 40 (2001) 518-524